Larimar Therapeutics to present nomlabofusp study data at International Congress for Ataxia Research
LRMR•Larimar Therapeutics will present three nomlabofusp posters at the International Congress for Ataxia Research in Atlanta on November 12, 2026, including previously disclosed interim clinical data and new analyses of plasma lipids and gene expression.
1. Three posters planned
Larimar Therapeutics will present three posters on nomlabofusp at the International Congress for Ataxia Research in Atlanta on November 12, 2026. They will include previously disclosed interim clinical data from an ongoing open-label study of long-term daily treatment in patients with Friedreich's ataxia, along with new analyses of plasma lipid profiles and gene expression responses to treatment.
